Effects of a Long-Term Wearable Activity Tracker-Based Exercise Intervention on Cardiac Morphology and Function of Patients with Cystic Fibrosis

• Published in: Sensors (Basel, Switzerland) Switzerland), 2022-06, Vol.22 (13), p.4884
• Main Authors: Anifanti, Maria, Giannakoulakos, Stavros, Hatziagorou, Elpis, Kampouras, Asterios, Tsanakas, John, Deligiannis, Asterios, Kouidi, Evangelia
• Format: Article
• Language: English
• Subjects: 6-min walking test; Abnormalities; Cystic fibrosis; Cystic Fibrosis - complications; Cystic Fibrosis - therapy; echocardiography; Exercise; Exercise Therapy; exercise training; Fitness Trackers - adverse effects; Fitness training programs; Flow velocity; Humans; Hypertension; Intervention; Patients; Physical fitness; Physical training; Pulmonary arteries; Pulmonary hypertension; Quality of Life; Systolic pressure; Ventricular Dysfunction, Right - etiology; Walking; wearable activity trackers; Wearable technology
• ISSN: 1424-8220; 1424-8220
• DOI: 10.3390/s22134884

Several studies have shown that patients with cystic fibrosis (CF), even at a young age, have pulmonary and cardiac abnormalities. The main complications are cardiac right ventricular (RV) systolic and/or diastolic dysfunction and pulmonary hypertension, which affects their prognosis. Exercise training (ET) is recommended in patients with CF as a therapeutic modality to improve physical fitness and health-related quality of life. However, questions remain regarding its optimal effective and safe dose and its effects on the patients’ cardiac function. The study aimed to provide a wearable activity tracker (WAT)-based ET to promote physical activity in CF patients and assess its effects on cardiac morphology and function. Forty-two stable CF individuals (aged 16.8 ± 3.6 years) were randomly assigned to either the intervention (Group A) or the control group (Group B). Group A participated in a 1-year WAT-based ET program three times per week. All patients underwent a 6-min walking test (6-MWT) and an echocardiographic assessment focused mainly on RV anatomy and function at the baseline and the end of the study. RV systolic function was evaluated by measuring the tricuspid annular plane systolic excursion (TAPSE), the systolic tricuspid annular velocity (TVS’), the RV free-wall longitudinal strain (RVFWSL), and the right ventricular four-chamber longitudinal strain (RV4CSL). RV diastolic function was assessed using early (TVE) and late (TVA) diastolic transtricuspid flow velocity and their ratio TVE/A. Pulmonary artery systolic pressure (PASP) was also estimated. In Group A after ET, the 6MWT distance improved by 20.6% (p < 0.05), TVA decreased by 17% (p < 0.05), and TVE/A increased by 13.2% (p < 0.05). Moreover, TAPSE, TVS’, RVFWSL, and RV4CSL increased by 8.3% (p < 0.05), 9.0% (p < 0.05), 13.7% (p < 0.05), and 26.7% (p < 0.05), respectively, while PASP decreased by 7.6% (p < 0.05). At the end of the study, there was a significant linear correlation between the number of steps and the PASP (r = −0.727, p < 0.01) as well as the indices of RV systolic function in Group A. In conclusion, WAT is a valuable tool for implementing an effective ET program in CF. Furthermore, ET has a positive effect on RV systolic and diastolic function.